Company Description
Natera, Inc., a diagnostics company, provides molecular testing services worldwide.
Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test.
In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners.
It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays.
The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012.
Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
| Country | United States |
| Founded | 2003 |
| IPO Date | Jul 2, 2015 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 4,434 |
| CEO | Steven Chapman |
Contact Details
Address: 13011 McCallen Pass, Building A Austin, Texas 78753 United States | |
| Phone | 650 980 9190 |
| Website | natera.com |
Stock Details
| Ticker Symbol | NTRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001604821 |
| CUSIP Number | 632307104 |
| ISIN Number | US6323071042 |
| Employer ID | 01-0894487 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Steven Leonard Chapman | Chief Executive Officer and Director |
| Dr. Matthew Rabinowitz Ph.D. | Co-Founder and Executive Chairman |
| John Fesko | President and Chief Business Officer |
| Michael B. Brophy M.B.A. | Chief Financial Officer |
| Solomon Moshkevich M.B.A. | President of Clinical Diagnostics |
| Jonathan Sheena M.Eng. | Co-Founder and Director |
| Olesya A. Anisimova CPA | Chief Accounting Officer |
| Rishi Kacker | Chief Technology Officer |
| Eric A. Evans Ph.D. | Chief Scientific Officer |
| Daniel Rabinowitz L.L.M. | Secretary and Chief Legal Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| May 1, 2025 | 144 | Filing |
| May 1, 2025 | 144 | Filing |
| May 1, 2025 | 144 | Filing |
| Apr 29, 2025 | 144 | Filing |
| Apr 24, 2025 | ARS | Filing |
| Apr 24, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 24, 2025 | 144 | Filing |